Related Experiment Video
Updated: Dec 20, 2025
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
Published on: June 7, 2016
The Effect of (E)-1-(4'-aminophenyl)-3-phenylprop-2-en-1-one on MicroRNA-18a, Dicer1, and MMP-9 Expressions against
Ida Ayu Ika Wahyuniari1, I Gusti Kamasan Nyoman Arijana1, Ni Putu Sriwidyani2
1Department of Histology, Faculty of Medicine, Udayana University, Bali, Indonesia.
Background:
Most of breast cancer patients are estrogen receptor alpha-positive and have high resistance and side effect of chemotherapeutic drug. Therefore, discovering an effective anticancer agent is needed. This research explored the effect of (E)-1-(4'-aminophenyl)-3-phenylprop-2-en-1-one (APE) on miR-18a, Dicer1, and MMP-9 expressions.
Methods:
Twenty four female Sprague-Dawley rats were invetigated in this study. The rats were divided into 6 groups of 4. G1 was considered as normal rat. G2, G3, T1, T2, and T3 were given DMBA 20 mg/kgBW twice a week for 5 weeks to induce mammary cancer. After being affiliated with cancer, G2 was given vehicle and G3 was treated with tamoxifen. T1, T2, and T3 were treated with APE intraperitoneally everyday for 21 days at doses of 5, 15, and 45 mg/kgBW/day, respectively. Blood plasma was collected to measure miR-18a expression using qRT-PCR. Mammary tissues were also collected to determine Dicer1 and MMP-9 expressions by using immunohistochemistry.
Results:
The results showed significant down-regulation of miR-18a relative expression and up-regulation of Dicer1 expression in G3 and T1 compared to G2 (P<0.05). MMP-9 expression has significant decrease in T1 compared to G2 (P<0.05).
Conclusion:
APE can decrease miR-18a and MMP-9 expressions and increase Dicer1 expression in rat mammary cancer. Therefore, this compound could be a candidate of novel anticancer.
Insights
(E)-1-(4'-aminophenyl)-3-phenylprop-2-en-1-one (APE) shows promise as an anticancer agent by down-regulating miR-18a and MMP-9 while up-regulating Dicer1 in rat mammary cancer models.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Estrogen receptor alpha-positive breast cancer exhibits resistance to chemotherapy, necessitating novel therapeutic agents.
- Current treatments for breast cancer often involve chemotherapeutic drugs with significant side effects.
- There is a critical need for effective anticancer agents with improved safety profiles.
Purpose of the Study:
- To investigate the anticancer effects of (E)-1-(4"-aminophenyl)-3-phenylprop-2-en-1-one (APE).
- To evaluate the impact of APE on the expression of miR-18a, Dicer1, and MMP-9 in a rat model of mammary cancer.
- To explore APE as a potential novel therapeutic candidate for breast cancer treatment.
Main Methods:
- DMBA was used to induce mammary cancer in Sprague-Dawley rats, divided into control, vehicle, tamoxifen, and varying APE dose groups.
- Quantitative reverse transcription PCR (qRT-PCR) was employed to measure miR-18a expression in blood plasma.
- Immunohistochemistry was utilized to determine Dicer1 and MMP-9 expression levels in mammary tissues.
Main Results:
- A significant down-regulation of miR-18a relative expression was observed in rats treated with APE (T1 group) and tamoxifen (G3) compared to the vehicle control (G2).
- Dicer1 expression was significantly up-regulated in the T1 and G3 groups relative to the G2 group.
- MMP-9 expression showed a significant decrease in the T1 group compared to the G2 group.
Conclusions:
- APE demonstrated the ability to decrease miR-18a and MMP-9 expression in rat mammary cancer.
- APE treatment led to an increase in Dicer1 expression in the studied rat model.
- These findings suggest that APE holds potential as a novel anticancer therapeutic agent.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
02:23Abnormal Proliferation